Meningeal Worm in Alpacas: Prevention, Treatment, and Why Gut Parasites Are Different

If you are new to alpacas, the word “deworming” can make parasite control sound much simpler than it really is.

Give a dewormer, kill the worms, and move on. Right? Not exactly.

In alpacas, three very different situations are often lumped together under the word “deworming”:

• Preventing meningeal worm before it reaches the nervous system.
• Treating meningeal worm after infection is suspected or neurologic signs have appeared.
• Managing gastrointestinal parasites such as barber pole worm and other parasites living in the digestive tract.

Some of the same medications may appear in more than one of these conversations, which is where much of the confusion begins. An alpaca receiving injectable ivermectin for meningeal-worm prevention, for example, can still have a significant gastrointestinal parasite burden.

Understanding why starts with understanding what meningeal worm actually is.

What is meningeal worm?

Meningeal worm, or Parelaphostrongylus tenuis, is a parasitic roundworm commonly associated with white-tailed deer. Deer are the parasite’s normal host. Infected deer generally tolerate the parasite well and can shed larvae into the environment. Snails and slugs then become intermediate hosts.

An alpaca becomes infected accidentally, usually while grazing, when it consumes an infected slug, snail, or vegetation carrying one. Once inside an alpaca, the larvae do not behave like an ordinary intestinal worm. They migrate toward the spinal cord and brain.

Because alpacas are abnormal, or “dead-end,” hosts, the parasite generally does not complete its normal reproductive life cycle. Instead, its migration through the nervous system can cause significant inflammation and neurologic injury. (Merck Veterinary Manual)

That is why meningeal worm is so different from the parasites we commonly find on a fecal exam.

What might meningeal worm look like?

Clinical signs depend on where the parasite is migrating and what part of the nervous system has been damaged.

An affected alpaca might become uncoordinated, stumble, drag a rear leg, appear weak in the hindquarters, have difficulty rising, develop a head tilt, circle, or show other unusual neurologic behavior. Severe cases may progress to an inability to stand. The signs can also be asymmetric - one side may appear worse than the other and early signs can be subtle.

When neurologic signs are present, time matters. Current veterinary guidance emphasizes beginning treatment as early as possible when meningeal worm is suspected because neurologic injury can become severe or permanent. (Merck Veterinary Manual)

Can you diagnose meningeal worm with a fecal?

Generally, no. This is another major difference between meningeal worm and gastrointestinal parasites.

Because alpacas are dead-end hosts, meningeal worms typically do not mature and reproduce normally within them. That means an alpaca with meningeal worm is not simply shedding meningeal-worm eggs or larvae in its manure for us to identify on a routine fecal exam. (Merck Veterinary Manual)

Diagnosis in a living animal can be difficult. A veterinarian may consider the animal’s neurologic signs, geography, exposure risk, examination findings, and sometimes cerebrospinal-fluid testing.

So a “clean fecal” does not rule out meningeal worm.

Prevention and treatment are not the same thing.

This is probably the most important distinction to understand.

With prevention, the goal is to kill susceptible meningeal-worm larvae after exposure but before they can reach and seriously damage the central nervous system.

With treatment, we are dealing with an alpaca in which infection is already suspected and the parasite may already be affecting the spinal cord or brain.

The medications, urgency, and objectives are different.

Does every alpaca need preventive medication?

No, and we think this distinction is important. There is not one management decision that every alpaca farm must make.

You may hear different recommendations from camelid veterinarians. Some farms in meningeal-worm areas elect to use a regular injectable ivermectin protocol. Others place greater emphasis on environmental management and rapid treatment of suspected cases because of concerns about repeated anthelmintic exposure and drug-resistant gastrointestinal parasites.

Both sides of that discussion involve real risks.

Current Merck Veterinary Manual guidance describes prevention as preferable to treating established clinical disease and lists monthly injectable ivermectin as a preventive option. The same guidance also warns that repeated ivermectin use for meningeal-worm prevention can contribute to the development of ivermectin-resistant gastrointestinal parasites. (Merck Veterinary Manual)

For clarity, the resistance concern here involves the gastrointestinal parasites repeatedly exposed to ivermectin, not meningeal worm becoming resistant within the alpaca. Because alpacas are dead-end hosts for meningeal worm, the parasite does not mature, reproduce, and pass resistant offspring from the alpaca back into the environment. The concern is that routine ivermectin exposure can select for resistant gut parasites, making ivermectin increasingly unreliable for gastrointestinal parasite control on affected farms.

This article is not saying every alpaca owner should routinely give ivermectin. The decision should take into account geography, deer pressure, pasture conditions, slug and snail exposure, previous cases on the farm, parasite resistance, and the recommendations of a veterinarian familiar with camelids.

Why Elderwood chooses prevention.

At Elderwood, we have experienced meningeal worm firsthand. After seeing what neurologic disease can do to an alpaca, it is something we personally never want to watch another animal go through if we can reasonably reduce that risk.

For that reason, we choose to utilize a preventive protocol in consultation with our veterinarian. That is our management decision based partly on our own experience - not a statement that every alpaca farm must make the same choice.

We also recognize the downside: repeated ivermectin exposure can contribute to gastrointestinal parasite resistance. That makes it especially important for us to understand exactly what the ivermectin is and is not being used to accomplish.

If you choose to use a preventive protocol.

Injectable ivermectin and doramectin (Dectomax®) are two medications that have been used in meningeal-worm prevention programs. Their purpose is to kill susceptible migrating larvae before those larvae reach the central nervous system.

It is important to understand what “prevention” means in this context. These medications do not prevent an alpaca from encountering the parasite. They are not vaccines, repellents, or barriers against slugs and snails. Rather, they are used in an attempt to interrupt the parasite after exposure, but before neurologic migration occurs.

Current Merck Veterinary Manual guidance describes monthly injectable ivermectin as one approach to prevention, while also acknowledging that repeated ivermectin exposure can contribute to resistance among gastrointestinal parasites. (Merck Veterinary Manual: Meningeal Worm)

Dr. Pamela Walker’s Camelid Medicine Cabinet lists both injectable ivermectin and doramectin (Dectomax®) as preventive options. Her reference describes 1% injectable ivermectin administered subcutaneously every 30–45 days and Dectomax every 45–60 days, noting the longer referenced interval for Dectomax. Her guidance also specifically distinguishes injectable ivermectin from oral or topical ivermectin for meningeal-worm prevention. (Dr. Pamela Walker’s Camelid Medicine Cabinet – 2025)

These are veterinary reference protocols, not a prescription for every herd. Recommendations vary among veterinarians and published sources, and the appropriate medication, dose, route, and interval should be determined with a veterinarian familiar with camelids. Alpaca medications are also commonly used extra-label, so formulation, concentration, weight, age, pregnancy status, concurrent illness, and other individual factors matter. (Merck Veterinary Manual: Herd Health of Llamas and Alpacas)

Environmental management matters too. Keeping deer away from alpaca paddocks where practical, reducing chronically wet areas, and decreasing habitat favorable to slugs and snails can all be part of reducing exposure. (Merck Veterinary Manual: Meningeal Worm Prevention and Control)

For farms that choose a preventive medication protocol, it is also important to remember why the medication is being given. An ivermectin or Dectomax injection used for meningeal-worm prevention should not be assumed to have simultaneously treated the alpaca’s gastrointestinal parasites. That is a separate parasite-management question, which we will discuss below.

What if the alpaca already has meningeal worm?

Now we are having an entirely different conversation.

An alpaca showing neurologic signs consistent with meningeal worm should be treated as a veterinary emergency. At that point, the objective is no longer simply to intercept a newly acquired larva. Treatment needs to address the migrating parasite, control inflammation and pain associated with the neurologic disease, and support the alpaca while its nervous system has an opportunity to recover.

Current Merck Veterinary Manual guidance for suspected P. tenuis in camelids describes fenbendazole at 50 mg/kg (approximately 23 mg/lb) orally every 24 hours for five days, along with an NSAID and supportive care. Merck’s broader camelid drug reference gives a fenbendazole treatment range of 30–50 mg/kg orally every 24 hours for five days. (Merck Veterinary Manual: P. tenuis Treatment - Merck: Selected Drugs Used in Llamas and Alpacas)

For alpaca owners who are more accustomed to dosing in mL or cc, 50 mg/kg is approximately 23 mg/lb. When using a 100 mg/mL (10%) fenbendazole suspension, that works out to approximately 23 mL (cc) per 100 lb of body weight. As an example, a 150 lb alpaca would receive approximately 34–35 mL of a 100 mg/mL suspension at that treatment dose.

Dr. Pamela Walker’s Camelid Medicine Cabinet similarly describes high-dose fenbendazole at approximately 23 mg/lb (50 mg/kg) for meningeal-worm treatment. Using a 100 mg/mL suspension, that is approximately 23 mL per 100 lb. Her referenced treatment duration extends from five to ten days, illustrating that published camelid protocols are not completely uniform. (Dr. Pamela Walker’s Camelid Medicine Cabinet – 2025)

Because fenbendazole products are available in different concentrations, the mL or cc amount cannot be used without first confirming the concentration of the specific product. A dose expressed as 23 mL per 100 lb applies only to a 100 mg/mL product; a different concentration requires a different volume.

The differences among published protocols are also an important reminder that these references are meant to help owners understand treatment, not to create a one-size-fits-all farm recipe. Suspected meningeal worm warrants prompt veterinary involvement, and the veterinarian managing the case should determine the appropriate drug, concentration, dose, duration, anti-inflammatory therapy, and supportive care for the individual alpaca.

Don’t forget the inflammation.

Killing the parasite is only part of treating meningeal worm. A significant part of the damage associated with the disease comes from inflammation within and around the nervous system, which makes controlling inflammation and pain an important part of treatment.

Banamine® (flunixin meglumine) is one NSAID commonly used in camelids, and it has been a successful and important part of treatment in cases we have personally managed at Elderwood. Banamine does not kill meningeal worm. Its role is different: it helps control pain and inflammation while the antiparasitic medication addresses the parasite itself.

Current Merck Veterinary Manual guidance includes an NSAID as part of treatment for suspected P. tenuis. Merck’s current camelid drug reference lists flunixin meglumine at 1.1–2.2 mg/kg IV every 24 hours. For owners more familiar with mL or cc, when using the common 50 mg/mL injectable concentration, that is approximately 1–2 mL (cc) per 100 lb of body weight. The dose, route, duration, and frequency should still be determined by the veterinarian managing the individual case. (Merck Veterinary Manual)

Dr. Pamela Walker’s Camelid Medicine Cabinet also includes Banamine as a commonly used anti-inflammatory in camelids, while emphasizing an important caution: flunixin can increase the risk of kidney injury in a dehydrated animal and may contribute to gastrointestinal ulceration with prolonged use. Hydration status therefore matters when deciding whether and how Banamine should be used. (Dr. Pamela Walker’s Camelid Medicine Cabinet – 2025)

Because of those risks, we would not treat the published dose as a one-size-fits-all farm recipe. The choice of NSAID, dose, route, duration, hydration support, and monitoring should be made with the veterinarian managing the case.

Current Merck guidance also advises against corticosteroids in suspected P. tenuis cases, even though steroids may appear in some older meningeal-worm treatment protocols. (Merck Veterinary Manual: P. tenuis Treatment)

Severe cases may need much more than medication.

An alpaca that is weak, struggling to walk, or unable to stand may require substantial supportive care. That can include hydration, nutritional support, repositioning to prevent secondary complications, physical rehabilitation, sling support, and, in severe cases, hospitalization or referral care.

This is part of why “we’ll just treat it if we get it” and “we choose to prevent it” can feel very different to someone who has actually cared for an affected alpaca.

Treatment can absolutely be successful, but neurologic disease can also be devastating, recovery can be prolonged, and some damage may be permanent. Merck describes the prognosis once clinical neurologic disease develops as guarded to poor. (Merck Veterinary Manual)

So where do gut parasites fit into all of this?

Now we have to mentally leave the brain and spinal cord and go back to the digestive tract.

Common gastrointestinal parasites in alpacas include strongyle-type worms such as Haemonchus contortus, the barber pole worm, along with Trichostrongylus, Cooperia, Nematodirus, Camelostrongylus, and others. Whipworms, Capillaria, and tapeworms may also occur. Coccidia are another common concern, but they are protozoa rather than worms, so they require a different approach again.

These parasites differ from meningeal worm because many live, feed, mature, and reproduce within the alpaca’s gastrointestinal system. That means a quantitative fecal examination can often provide useful information about what is happening.

This is where fecals matter.

With gastrointestinal parasites, we usually have the opportunity to be much more targeted.

A fecal can help identify parasite types and quantify the number of eggs or oocysts being shed. The animal’s clinical condition matters too - body condition, anemia, weight change, diarrhea, appetite, age, pregnancy status, and other factors may all affect whether treatment is appropriate.

A fecal isn’t perfect. An animal can have immature parasites that are not yet producing eggs, and egg counts do not always perfectly predict the number of adult parasites present, but it gives us information we simply do not get by blindly administering a dewormer.

Once treatment is chosen, repeat fecal testing can help determine something extremely important - did the medication actually work?

Why injectable ivermectin should not be considered your gut-parasite program.

This may be the most important practical point in the entire article.

An alpaca receiving injectable ivermectin for meningeal-worm prevention should not automatically be considered “dewormed” for gastrointestinal parasites. Ivermectin is an anthelmintic and can affect susceptible gastrointestinal nematodes, so it would be too absolute to say that injectable ivermectin is biologically incapable of killing a gut worm.

The problem is that we cannot depend on it to control the GI parasites present on a particular alpaca farm. Dr. Walker’s camelid reference specifically notes that ivermectin and doramectin do not cover several important parasites, including Nematodirus, whipworms, Capillaria, and tapeworms, and describes their effectiveness against ordinary strongyle-type infections as limited on many farms. (Dr. Pamela Walker’s Camelid Medicine Cabinet – 2025)

Even more importantly, ivermectin resistance in alpaca gastrointestinal parasites is documented. A 2010 study performed on South American camelid farms in Georgia tested subcutaneously injected ivermectin on an alpaca farm. The researchers found gastrointestinal nematode resistance to ivermectin in the alpacas studied. (ScienceDirect)

Research from Australia has documented the same larger problem. One study found ivermectin efficacy of only 35% against a resistant Haemonchus contortus population, and a later multicenter study found ivermectin ineffective by fecal egg-count-reduction criteria on all ten alpaca farms where it was tested. (PubMed Central (PMC))

That doesn’t mean ivermectin fails against every GI worm on every farm. It means something much more useful - d0 not assume that an ivermectin injection given for meningeal-worm prevention has successfully treated an alpaca’s gastrointestinal parasites.

Why routinely “rotating dewormers” isn’t the answer either.

For years, livestock owners were frequently encouraged to deworm animals on a schedule and periodically rotate among different products. We now understand the downside of that approach much better.

Every time a parasite population is exposed to an deworming medication, susceptible worms are killed while resistant worms are more likely to survive and reproduce. Over time, repeated treatment can select heavily for resistance.

That is particularly relevant to meningeal-worm prevention because a drug intended to protect the alpaca from P. tenuis may simultaneously expose the alpaca’s GI parasites to that same drug. Merck specifically calls out this unintended consequence of monthly ivermectin prevention. (Merck Veterinary Manual) Resistance isn’t limited to ivermectin. Research in alpacas has documented resistance involving several commonly used anthelmintic classes. (PubMed Central (PMC))

That is why there really isn’t a universal answer to: “What’s the best dewormer for alpacas?”

A better question is:“What parasite am I trying to treat, and what still works on my farm?”

The simplest way to put it.

If all of this still feels complicated, think about it this way.

Meningeal-worm prevention is an attempt to stop a migrating parasite before it reaches the spinal cord or brain.

Clinical meningeal-worm treatment is an aggressive response after infection is suspected, generally involving high-dose fenbendazole, control of inflammation with an NSAID such as Banamine when appropriate, supportive care, and close veterinary involvement.

Gastrointestinal parasite control is a separate management program built around identifying the parasite, evaluating the animal, choosing an effective treatment when needed, and confirming that the treatment worked.

An alpaca can absolutely be receiving ivermectin for the first purpose while still needing an entirely different approach for the third.

Where we land at Elderwood.

We don’t believe responsible parasite management means giving every available medication “just in case.” We also don’t believe there is one protocol every alpaca farm must follow.

For meningeal worm, we choose prevention because we have personally experienced the disease and have seen what it can do. We make that choice knowing that repeated ivermectin exposure comes with a legitimate resistance concern, which makes careful GI-parasite monitoring even more important. Another farm and its veterinarian may weigh those risks differently.

What matters most is understanding why a medication is being given. If we are administering ivermectin to help prevent meningeal worm, we should call it what it is: meningeal-worm prevention. We should not automatically call that alpaca “dewormed.” If a fecal shows a gastrointestinal parasite problem, that is a new question requiring its own diagnosis, treatment decision, and follow-up.  If an alpaca begins showing unexplained neurologic signs, that is no longer a routine parasite-management question at all - it's time to call the veterinarian.

A final note.

This article is intended to make a complicated subject easier to understand, not to replace veterinary care. Antiparasitic and anti-inflammatory medications are commonly used extra-label in alpacas, and individual treatment can change based on weight, age, pregnancy status, hydration, kidney function, concurrent illness, parasite resistance, drug formulation, and other factors.

Work with a veterinarian familiar with camelids to develop both a meningeal-worm strategy and a gastrointestinal-parasite program appropriate for your herd.

Primary veterinary and research sources used for this article: the Merck Veterinary Manual’s current camelid and Parelaphostrongylus tenuis guidance (Merck Veterinary Manual); Cornell Wildlife Health Laboratory’s P. tenuis reference (Cornell Wildlife Health Lab); Pamela G. Walker, DVM, MS, DACVIM-LA’s Camelid Medicine Cabinet (Dr. Pamela Walker’s Camelid Medicine Cabinet – 2025); Gillespie et al.’s U.S. camelid anthelmintic-resistance study (PubMed); and published alpaca anthelmintic-resistance research from Australia (PubMed Central (PMC)).